Theravance Biopharma, Inc. (TBPH)
NASDAQ: TBPH · Real-Time Price · USD
10.91
-0.25 (-2.24%)
At close: Aug 1, 2025, 4:00 PM
10.90
-0.01 (-0.09%)
After-hours: Aug 1, 2025, 4:04 PM EDT
HashiCorp Employees
Theravance Biopharma had 97 employees as of December 31, 2024. The number of employees decreased by 2 or -2.02% compared to the previous year.
Employees
97
Change (1Y)
-2
Growth (1Y)
-2.02%
Revenue / Employee
$672,845
Profits / Employee
-$601,371
Market Cap
545.01M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 97 | -2 | -2.02% |
| Dec 31, 2023 | 99 | -12 | -10.81% |
| Dec 31, 2022 | 111 | -48 | -30.19% |
| Dec 31, 2021 | 159 | -200 | -55.71% |
| Dec 31, 2020 | 359 | 43 | 13.61% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
TBPH News
- 5 days ago - Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 - PRNewsWire
- 10 days ago - Theravance Biopharma to Participate in an Upcoming Investor Conference - PRNewsWire
- 5 weeks ago - Theravance Biopharma Announces Approval of YUPELRI® (revefenacin) by China's NMPA - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million - PRNewsWire
- 2 months ago - Theravance Biopharma, Inc. (TBPH) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress - PRNewsWire
- 3 months ago - Theravance Biopharma, Inc. Reports First Quarter 2025 Financial Results and Provides Corporate Update - PRNewsWire
- 3 months ago - Theravance to Present Analyses of Ampreloxetine and Neurogenic Orthostatic Hypotension at the 2025 International MSA Congress - PRNewsWire